A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS
Stopped The study was withdrawn prior to enrollment after a comprehensive review of the biosimilars market and the company's global manufacturing network.
Conditions
Interventions
- DRUG: PF-06439535 (CN)
- DRUG: bevacizumab - EU
Sponsor
Pfizer